Futibatinib was tolerable and had a manageable safety profile.1Limited phase 1 data suggest futibatinib may also have antitumor activity at a lower dose (16 mg QD), with fewer dose modifications required for adverse events.2The aim of FOENIX-CCA4is to confirm the clinical benefit of fu...